Christopher John Kenney Sells 1,410 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Key Points

• Christopher John Kenney sold 1,410 shares of Xenon Pharmaceuticals on March 13 at an average price of $55.23 for $77,874, leaving him with 7,069 shares (a 16.63% reduction in his position).
• Company catalysts and analyst support: Xenon completed the X‑TOLE2 Phase‑3 study, closed an upsized public offering that raised about $747.5M, and saw multiple broker price‑target increases that leave the stock with an average "Buy" rating and a ~$71.94 target.
• Near‑term risks: Several insiders (including the CEO) disclosed large open‑market sales and the recent equity raise increases share count, creating potential dilution pressure on near‑term per‑share metrics despite stronger cash runway.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) insider Christopher John Kenney sold 1,410 shares of the firm's stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $55.23, for a total transaction of $77,874.30. Following the transaction, the insider owned 7,069 shares of the company's stock, valued at approximately $390,420.87. This represents a 16.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Christopher John Kenney also recently made the following trade(s):

• On Tuesday, March 10th, Christopher John Kenney sold 2,771 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $60.11, for a total value of $166,564.81.

Xenon Pharmaceuticals Stock Performance

Shares of XENE stock traded down $2.67 during trading hours on Friday, hitting $55.23. The company had a trading volume of 3,849,961 shares, compared to its average volume of 1,923,723. The firm has a market capitalization of $4.59 billion, a price-to-earnings ratio of -12.67 and a beta of 0.91. Xenon Pharmaceuticals Inc. has a 12 month low of $26.74 and a 12 month high of $63.95. The firm's fifty day moving average is $43.71 and its 200 day moving average is $41.92.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same quarter last year, the business earned ($0.84) earnings per share. On average, sell-side analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of XENE. Elevation Point Wealth Partners LLC bought a new position in shares of Xenon Pharmaceuticals in the 2nd quarter valued at about $32,000. Danske Bank A S acquired a new stake in shares of Xenon Pharmaceuticals in the 3rd quarter valued at about $32,000. Blue Trust Inc. raised its position in Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 717 shares during the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Xenon Pharmaceuticals in the fourth quarter worth $33,000. Finally, Aster Capital Management DIFC Ltd bought a new stake in Xenon Pharmaceuticals during the 3rd quarter worth about $39,000. Institutional investors own 95.45% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. HC Wainwright upped their target price on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a "buy" rating in a report on Tuesday. Stifel Nicolaus set a $66.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 10th. Bank of America reaffirmed a "buy" rating on shares of Xenon Pharmaceuticals in a research note on Monday. Robert W. Baird raised their price objective on shares of Xenon Pharmaceuticals from $63.00 to $97.00 and gave the stock an "outperform" rating in a report on Monday. Finally, Wells Fargo & Company lifted their target price on shares of Xenon Pharmaceuticals from $49.00 to $68.00 and gave the company an "overweight" rating in a research note on Tuesday. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Xenon Pharmaceuticals presently has an average rating of "Buy" and an average price target of $71.94.

More Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase‑3 progress — Xenon completed the X‑TOLE2 Phase 3 study, placing XEN1101 (azetukalner) in focus for epilepsy investors and supporting a planned NDA timeline; this derisks the lead program and underpins longer‑term commercial value. Read More.
• Positive Sentiment: Big institutional interest — Reports note major funds increasing exposure (including a ~$200M position cited by The Motley Fool), which can add buying pressure into the stock on further positive catalysts. Read More.
• Positive Sentiment: Balance‑sheet boost — Xenon closed an upsized public offering that raised approximately $747.5M of gross proceeds, extending runway for Phase 3/commercial preparations and reducing near‑term financing risk. Read More.
• Positive Sentiment: Analyst upgrades — Several brokers raised price targets and reiterated Buy/Overweight ratings (Deutsche Bank, HC Wainwright, Wells Fargo and others), which can support short‑term demand. Read More.
• Neutral Sentiment: Model adjustments — HC Wainwright revised multi‑year EPS forecasts (improving FY2028–FY2030 assumptions but nudging FY2027), reflecting evolving commercialization timing; useful for context but subject to change. Read More.
• Neutral Sentiment: Volume and momentum — The stock has seen elevated trading volume following the analyst activity and trial news, which can amplify intraday moves in either direction. Read More.
• Negative Sentiment: Insider selling — CEO Ian Mortimer and several other insiders disclosed large open‑market sales (hundreds of thousands of shares by the CEO), reducing insider ownership and raising optics concerns for some investors. Read More.
• Negative Sentiment: Dilution risk — The sizable share issuance (and initial underwriter option) that funded the ~$747.5M raise increases outstanding shares and can pressure near‑term per‑share metrics despite improving cash runway. Read More.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.